- Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
- Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
- Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
More ▼
Key statistics
On Friday, Blueprint Medicines Corp (BPMC:NSQ) closed at 93.00, -7.92% below its 52-week high of 101.00, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 92.76 |
---|---|
High | 94.98 |
Low | 90.47 |
Bid | 88.22 |
Offer | 96.64 |
Previous close | 90.73 |
Average volume | 684.39k |
---|---|
Shares outstanding | 61.23m |
Free float | 60.71m |
P/E (TTM) | -- |
Market cap | 5.56bn USD |
EPS (TTM) | -8.37 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼